Previous 10 | Next 10 |
Company Continues Accelerated Development of Candidate Pipeline and Patent Portfolio in Respiratory Medicine Space as Phase III Trial Proceeds Therapeutic Solutions International announced today data and filing of a patent covering the use of “gene silencing” i...
Company Eyes Targeting 17 Billion Dollar Market Using Universal Donor Adult Stem Cell Therapy Therapeutic Solutions International announced today filing with the Food and Drug Administration (FDA) an amendment to its currently open Phase III clinical trial requesting expansi...
Phase III Clinical Stage Company Demonstrates Superior Efficacy of Proprietary Stem Cell Apoptotic Body Based Drug Therapeutic Solutions International announced today new data demonstrating superior effects of the Company’s ApoptoCyte ™ procedure treated Ja...
Phase III Regenerative Medicine Company Creates Second-Generation Tailor-Made Cellular Therapies Therapeutic Solutions International reported the successful generation of gene-edited and/or gene-modified regenerative cells possessing mixtures of properties between mesenchyma...
Therapeutic Solutions International ( OTCPK:TSOI ) on Monday said it had been granted an emergency investigational new drug (IND) clearance by the U.S. FDA for expanded patient access to its JadiCell stem cell therapy for the treatment of COVID-19. Shares of the micro-cap ...
Commercially Available Nutraceutical Developed by Phase III Stem Cell Biotechnology Company Continues to Receive Independent Validation of Potential Benefit in SARS-CoV-2 Strains Therapeutic Solutions International, a clinical-stage biotechnology company, commented today on ...
Former Head of Novartis Respiratory and Allergy Medicine to Advise Clinical Stage Stem Cell Company on COVID-19 and COPD Programs Therapeutic Solutions International announced today the appointment of Dr. Donald Banerji to the Company’s Scientific Advisory Board. ...
Therapeutic Solutions International (OTCPK:TSOI) on Monday said it got investigational new drug application number 28508 from the U.S. Food and Drug Administration (FDA) for its proposed clinical study evaluating its adult stem cell product JadiCell for the treatment of chronic obstructi...
Phase III Adult Stem Cell Company Continues Expansion into Pulmonary Diseases Therapeutic Solutions International announced today receiving Investigational New Drug application number #28508 from the United States Food and Drug Administration for its proposed clinical trial ...
Therapeutic Solutions International Continues Parallel Development of COPD Program in Conjunction with Pivotal Clinical Trial in COVID-19 Therapeutic Solutions International announced today new data demonstrating enhancement of therapeutic activities of the JadiCell™ ...
News, Short Squeeze, Breakout and More Instantly...
Therapeutic Sltns Intl Company Name:
TSOI Stock Symbol:
OTCMKTS Market:
Therapeutic Sltns Intl Website:
Clinical Stage Stem Cell Company Granted Exclusivity on the Use of Specific Immune System Cells to Increase Efficacy of Stem Cells in Lung Inflammation Therapeutic Solutions International, Inc. (TSOI) announced today receipt of a Notice of Allowance from the United States Patent and Tra...
Therapeutic Solutions International Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distribution of its Shares to Shareholders of Parent Company Therapeutic Solutions International, Inc. (TSOI) Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distr...
Latest Patent to Complement Issued Claims on Viral Inhibition, Adaptive Immune Stimulation, and Brain Protection/Regeneration Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the abi...